AIGH Capital Management LLC Reduces Stake in PolyPid Ltd. $PYPD

AIGH Capital Management LLC reduced its stake in shares of PolyPid Ltd. (NASDAQ:PYPD) by 10.8% in the third quarter, Holdings Channel reports. The fund owned 1,065,128 shares of the company’s stock after selling 128,980 shares during the quarter. PolyPid accounts for about 1.0% of AIGH Capital Management LLC’s portfolio, making the stock its 25th largest position. AIGH Capital Management LLC owned approximately 0.07% of PolyPid worth $3,552,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Lumbard & Kellner LLC bought a new stake in shares of PolyPid in the 2nd quarter worth approximately $135,000. Institutional investors own 26.47% of the company’s stock.

PolyPid Stock Performance

NASDAQ:PYPD opened at $4.78 on Friday. The business’s fifty day moving average is $4.12 and its 200 day moving average is $3.71. The firm has a market cap of $76.00 million, a price-to-earnings ratio of -1.60 and a beta of 1.51. PolyPid Ltd. has a 52-week low of $2.30 and a 52-week high of $5.05.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.17. Equities analysts predict that PolyPid Ltd. will post -1.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PYPD has been the subject of several research reports. Citigroup reissued a “market outperform” rating on shares of PolyPid in a report on Monday, December 1st. Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Roth Mkm decreased their price objective on PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $12.40.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.